https://hdl.handle.net/20.500.14178/1 Faculties 2026-09-23T07:40:08Z https://hdl.handle.net/20.500.14178/3962 Switching Semiotic Styles: The Metachoices of Pandemic Communication Smith, Simon This book argues that a reflexive awareness of our semiotic style, our grasp on the world as it rolls over, can be empowering when our normal ways of going on come unstuck, opening up choices that are more event shaping than we realise. Stylistic orientations enact metachoices: choices that set the criteria for subsequent ones, setting up a cascade of conditioned, but not wholly determined, choices. Switching Semiotic Styles constitutes an appeal to broaden our usual repertoire of semiotic practice, channelling a common multimodal listening competence into a perspective interplay which changes the parameters of what can be known. Smith develops a research style constructively opposing the narrative and sonic turns in the social sciences, which he then uses to analyse three examples of communication from the Covid-19 pandemic: advice-giving by the WHO, legal disputes about public health restrictions and vaccine promotion videos. The work shows how individuals and societies arrange ongoingness oriented by both the motivational affordances of transformational goals and the modulating push of music-like patterns of becoming. This book will appeal to scholars interested in semiotics, communication theory, sound studies, organisational communication, health communication, sociology of health and illness, and language in social interaction. 2027-01-01T00:00:00Z https://hdl.handle.net/20.500.14178/3961 Online vs. Offline: Dichotomy Hinders the Development of Creative Potential Wanča, Nina Nekvindová, Terezie; Rusinko, Marcela; Tomáš, Winter Digital projects and virtual exhibitions are perceived as a space with great potential for presenting cultural heritage; however, the field of digital curatorship brings new challenges. This paper examines the relationship between online and offline exhibitions in the museum environment and points out that their dichotomous perception hinders the development of the creative potential of both formats. The text first places online exhibitions into a broader social context: it considers demographic changes and unequal access to cultural heritage, the experience of museum closures during the pandemic, the issue of overtourism, and the rise of AI. It further compares the key characteristics and differences of both types of exhibitions. It highlights that online exhibitions are neither simpler nor cheaper to produce, and they place new demands on creators in the areas of UX, UI, and digital storytelling. It also addresses the typology of online exhibitions-from databases and 3D tours to complex interactive projects-and the principles of navigation in digital space. In the section dedicated to digital curatorship, systemic barriers are identified based on research with direct stakeholders: the absence of an official digital curator position in the Czech Republic, insufficient institutional support, and the limited experience of both creators and visitors with this format. To fulfill the mission of museum institutions, it is important to seek out innovative ways of presentation. For museums to respond creatively to the diverse needs of visitors, a greater integration of online and offline exhibitions is advisable. 2026-01-01T00:00:00Z https://hdl.handle.net/20.500.14178/3960 Increase in second primary lung cancers in a nation-wide cohort study from Sweden Zitrický, František; Sundquist, Kristina; Sundquist, Jan; Försti, Asta; Hemminki, Akseli; Kaaks, Rudolf; Hemminki, Kari Jussi Background: We describe the occurrence of second primary lung cancers (SPLCs) and their determinant in Sweden. Methods: Nation-wide cancer registry from years 1961 to 2021 identified a total of 853 SPLCs. Results: The incidence of SPLCs increased almost linearly from 1980 onwards, equally for women and men and approximately equally after the four main histological types. SPLC included adenocarcinoma 63.9%, squamous cell carcinoma (SCC) 19.4%, small cell carcinoma 9.6% and large cell carcinoma 9.1%. The female cumulative probability (CumP) of SPLC after first adenocarcinoma in 10 years reached 0.019, after SCC 0.015 and after small and large cell carcinoma 2 0.008. The respective CumP for men were 0.013, 0.012, 0.002 and 0.005. While adenocarcinoma was often followed by second adenocarcinoma, after first non-adenocarcinoma SPLCs presented in diverse histologies. Relative risk of SPLC compared to first lung cancer was overall 3.59, higher for women (4.16) than for men (2.99) and approximately equally high after adenocarcinoma and SCC. In patients diagnosed before age 55 years, the relative risk was 6.68 for all, but after female adenocarcinoma it was 9.95 compared to 6.77 for males. The highest relative risks, up to 20-fold, were found after early onset female adenocarcinoma diagnosed after defined T stages. Conclusions: Although SPLCs are still rare their number is increasing rapidly and the relative risks compared to first lung cancer are substantial, qualifying selected groups of high-risk patients, such as early onset adenocarcinoma patients for early detection by CT screening when/if such tests become available. 2026-01-01T00:00:00Z https://hdl.handle.net/20.500.14178/3959 Catheter-Directed Thrombolysis in Intermediate-High-Risk Pulmonary Embolism Kroupa, Josef; Radvan, Martin; Mrózek, Jan; Sluka, Martin; Jirouš, Štěpán; Hlinomaz, Ota; Plíva, Milan; Pudil, Jan; Voběrková, Hana; Bartošková, Karolína; Poloczek, Martin; Kameník, Martin; Brabec, Michal; Lichnerová, Eva; Hutyra, Martin; Bernat, Ivo; Novák, Martin; Horáková, Johana; Jelínková, Lucie; Kníže, Tomáš; Toušek, Petr; Štěchovský, Cyril; Varhaník, Filip; Coufal, Zdeněk; Jarkovský, Jiří; Kočka, Viktor BACKGROUND: Whether catheter-directed thrombolysis improves clinical outcomes in patients with intermediate-high-risk pulmonary embolism, as compared with anticoagulation alone, is uncertain. METHODS: In this multicenter, open-label, randomized trial, we randomly assigned patients with intermediate-high-risk acute pulmonary embolism (defined by hemodynamic stability, a simplified Pulmonary Embolism Severity Index score of >=1, and right ventricular dysfunction plus an elevated level of cardiac troponin or natriuretic peptide) in a 1:1 ratio to receive catheter-directed thrombolysis with alteplase plus anticoagulation therapy (thrombolysis group) or anticoagulation therapy alone (standard-care group). The primary outcome was a composite of death from any cause, recurrence of pulmonary embolism, or cardiorespiratory decompensation or collapse within 7 days after randomization. Secondary outcomes included clinically relevant bleeding as defined by the Bleeding Academic Research Consortium, major bleeding as defined in the Global Use of Strategies to Open Occluded Coronary Arteries guidelines, and intracranial hemorrhage. RESULTS: A total of 558 patients underwent randomization; 280 were assigned to the thrombolysis group, and 278 to the standard-care group. The median age was 64 years, and 40.9% were female. A primary-outcome event occurred in 2 patients (0.7%) in the thrombolysis group and in 19 patients (6.8%) in the standard-care group (relative risk, 0.10; 95% confidence interval, 0.02 to 0.44; P<0.001); this difference was driven mainly by the lower incidence of cardiorespiratory decompensation or collapse in the thrombolysis group. By day 7, clinically relevant bleeding had occurred in 13 patients (4.6%) in the thrombolysis group and in 14 patients (5.0%) in the standard-care group (P = 0.85); major bleeding in 4 (1.4%) and 6 (2.2%), respectively (P = 0.54); and intracranial hemorrhage in 2 (0.7%) and none. One patient in the thrombolysis group died within 30 days, and 4 patients in the standard-care group died within 7 days. CONCLUSIONS: Among patients with intermediate-high-risk acute pulmonary embolism, catheter-directed thrombolysis with alteplase plus anticoagulation therapy led to a lower risk of death from any cause, recurrent pulmonary embolism, or cardiorespiratory decompensation or collapse within 7 days after randomization than anticoagulation therapy alone. (Funded by the Ministry of Health of the Czech Republic and others; PRAGUE-26 ClinicalTrials.gov number, NCT05493163; EudraCT number, 2022-002218-18; European Union Clinical Trials number, 2024-516144-25-00.). 2026-01-01T00:00:00Z